4-Chloro-6-iodoquinazoline Synthesis Route & Bulk Supply (CAS 98556-31-1)
Optimizing Yield and Purity in Halogenated Quinazoline Production
Procurement managers and R&D chemists frequently encounter significant challenges when sourcing critical kinase inhibitor precursors. Inconsistent halogenation levels and residual starting materials often compromise the industrial purity required for downstream coupling reactions. Variability in the quality of this lapatinib intermediate can lead to failed batches during Suzuki coupling or nucleophilic substitution, resulting in costly delays. Ensuring a stable supply of material with verified analytical data is essential for maintaining production schedules and regulatory compliance in pharmaceutical manufacturing.
Technical Specifications and Analytical Verification
At NINGBO INNO PHARMCHEM CO.,LTD., we prioritize rigorous quality control to ensure every batch meets stringent pharmacopeial standards. Our manufacturing process utilizes advanced chromatographic and spectrometric methods to verify identity and assay. The following table outlines the key technical specifications for our commercial-grade material.
| Parameter | Specification |
|---|---|
| Product Name | 4-Chloro-6-iodoquinazoline |
| CAS Registry Number | 98556-31-1 |
| Molecular Formula | C8H4ClIN2 |
| Molecular Weight | 290.49 g/mol |
| Purity (HPLC) | ≥ 99.0% |
| Appearance | Off-white to Yellow Solid |
| Analysis Method | HPLC, 1H NMR, Mass Spectrometry |
Each shipment is accompanied by a comprehensive COA confirming compliance with these specifications. For detailed pricing tiers and availability, you may review our latest market analysis on 4-Chloro-6-Iodoquinazoline Bulk Price Global Manufacturer 2026.
Detailed Chemical Synthesis Route and Reaction Mechanism
The manufacturing process begins with the cyclization of 5-iodo-2-aminobenzoic acid. This starting material is reacted with formamide under controlled thermal conditions to generate 6-iodo-3H-quinazolin-4-one. This intermediate is then subjected to chlorination using phosphorus oxychloride in the presence of a base, such as triethylamine, within a toluene solvent system. This specific synthesis route is optimized to minimize side reactions and ensure high regioselectivity.
Following the reaction, the crude product undergoes rigorous purification steps, including quenching, extraction, and crystallization, to remove residual phosphorus species and unreacted precursors. This ensures the final 4-Chloro-6-iodoquinazoline is suitable for immediate use in subsequent nucleophilic substitution or cross-coupling steps without further refinement. Our process engineers continuously monitor reaction parameters to maintain consistency across large-scale production runs.
Factory-Direct Bulk Pricing Advantages and Supply Chain Stability
Securing a reliable source for critical intermediates is vital for executive planning and cost management. By eliminating intermediaries, we offer competitive bulk price structures that scale with your production volume. Our facility maintains strategic raw material reserves to mitigate supply chain disruptions, ensuring on-time delivery even during periods of high market demand. We support long-term contracts with fixed pricing options to help stabilize your operational budgets.
Whether you require standard grades or specific particle size distributions, our team is equipped to handle diverse manufacturing needs. We understand the importance of continuity in pharmaceutical supply chains and commit to providing transparent communication regarding inventory status and lead times.
Our dedication to quality and service makes NINGBO INNO PHARMCHEM CO.,LTD. a trusted partner for global pharmaceutical companies seeking reliable intermediate solutions.
For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.